Assessment of efficiency of therapy at patients with the gastroesophageal reflux disease in age aspect
https://doi.org/10.21518/2079-701X-2019-3-55-59
Abstract
The demand of work is connected with prevalence a gastroesophageal reflux disease (GERB) against the background of insufficient study of age features of a course of this disease in the senior age groups. The research cohort made 96 patients with GERB. All patients were divided by method of randomization into two equal groups by quantity: the first – the persons receiving пантопразол 40 mg/days, the second – омепразол in a dose of 20 mg/days. Comparative study of efficiency of reception of an omeprazol and pantoprazol in age aspect at patients with GERB from positions of assessment of indicators of the quality of life (QL) was carried out. Indicators of KZh estimated on a visual and analog scale and the questionnaire of SF-36. Direct correlation connection between the level of health of patients and the following factors is established: existence of heartburn, the general time рН <4.0, number of refluxes in a minute, duration of the most long reflux in minutes. It was reasoned it is shown that at persons of the senior age groups in treatment of GERB пантопразол is more effective medicine, than омепразол. Patients of young and average age of the convincing proof have advantages of a pantoprazol before omeprazoly is not found. The result of the carried-out therapy in many respects is defined by degree of commitment of the patient. Therefore the choice of optimum approach to purpose of concrete medicine has to be carried out taking into account assessment of its safety, availability and the acceptability from the point of view of the patient.
About the Authors
O. A. Denisova
Federal state-funded educational institution of the higher education «Omsk state medical university» of the Russian Ministry of Health
Russian Federation
Russian Federation
assistant to department of public health and health care,
644099, Omsk, Lenin St., 12
M. A. Livzan
Federal state-funded educational institution of the higher education «Omsk state medical university» of the Russian Ministry of Health
Russian Federation
Russian Federation
MD, the rector, the department chair of faculty therapy, occupational diseases,
644099, Omsk, Lenin St., 12
A. P. Denisov
Federal state-funded educational institution of the higher education «Omsk state medical university» of the Russian Ministry of Health
Russian Federation
Russian Federation
PhDs in Medicine., the associate professor of public health and health care,
644099, Omsk, Lenin St., 12
O. A. Kuhn
Federal state-funded educational institution of the higher education «Omsk state medical university» of the Russian Ministry of Health
Russian Federation
Russian Federation
assistant to department of public health and health care,
644099, Omsk, Lenin St., 12
References
1. El-Serag Н.В., Sweet S., Winchester C.C. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880.
2. Zhukova T.V. Gastroesophageal reflux disease in the practice of a physician. Med. current events. 2017;8:39-41. (In Russ.)
3. Mayev I.V., Andreev D.N., Dicheva D.T. Gastroesophageal reflux disease: from pathogenesis to therapeutic aspects. Consilium medicum. 2013;15(8):30-34. (In Russ.)
4. Livzan M. A., Denisova O. A. Peculiarities of supervision of patients of elderly and senile age with gastroesophageal reflux disease. Attending doctor. 2015;8:36-40. (In Russ.)
5. Mayev I.V., Samsonov A.A., Andreev N.D. Long-term combined therapy of GERD is a way to maintain the proper quality of life and a guarantee against the complicated course of the disease. Clinical perspectives of gastroenterology, hepatology. 2011;2:11-18. (In Russ.)
6. Order of the Ministry of health of the Russian Federation No. 722n of November 9, 2012 «on approval of the standard of specialized medical care for gastroesophageal reflux disease». (In Russ.)
7. Vakil N., Sander V. van Zanten, Peter Kahrilas et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006;101(8):1900-1920.
8. Lazebnik L.B., Tkachenko E.V., Abdulkhakov L.A., et al. Standards of diagnosis and treatment of acid-dependent and Helicobacter pylori-associated diseases: Gastroesophageal reflux disease. Vestn. practical. doctor’s. 2013;3:6-9. (In Russ.)
9. Dabrowski A., Stabuc B., Lazebnik L. Metaanalysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Gastroenterology Rev. 2018;13(1):6-15.
10. Ware J.E., Kosinski M., Keller S.D. SF-36 Physical and mental health summary scales: a user`s manual. Boston: The Health Institute, New England medical center, 1994.
11. Ivashkin V.T., Mayev I.V., Trukhmanov A.S. and others Gastro esophageal reflux disease: Clinical recommendations for diagnosis and treatment. M., 2014. (In Russ.)
12. Akhmedov V.A., Nozdrachov V.A. Modern views on the safety of long-term therapy with proton pump inhibitors. Literature review. RMJ. 2017;25(10):765-768. (In Russ.)
13. Armstrong D., Marshall J.K., Chiba N. et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults – update 2004. Can J. Gastroenterol. 2005;19(15):35.
Review
For citations:
Denisova OA, Livzan MA, Denisov AP, Kuhn OA. Assessment of efficiency of therapy at patients with the gastroesophageal reflux disease in age aspect. Meditsinskiy sovet = Medical Council. 2019;(3):55-59. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-55-59
Views:
605
Email this article 